Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression
Annals of the Rheumatic Diseases · 2024-04 · 83 (4) · 464-474
DOI: 10.1136/ard-2023-224919 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of the Rheumatic Diseases, 2024-04. Verfasst von Sofia Pitsigavdaki und 14 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology and Clinical Immunology, University of Crete School of Medicine, Heraklion, Greece. Hauptthemen laut MEDLINE: Arthritis, Lupus Erythematosus, Systemic, Skin Diseases. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pancretan Health Association, Research Account of the University of Crete.
Abstract (Originalsprache)
OBJECTIVES: Treatment targets in systemic lupus erythematosus (SLE) have been validated in unselected-in terms of severity-cohorts, which limits their generalisability. We assessed remission (Definition of Remission in SLE (DORIS)) and Lupus Low Disease Activity State (LLDAS) in a historical cohort of 348 patients with active moderate-to-severe disease and median follow-up of 5 years. METHODS: Active SLE was defined as Physician Global Assessment ≥1.5 and/or SLE Disease Activity Index 2000 ≥6, requiring therapy intensification. DORIS/LLDAS, organ damage, flares and adverse events were monitored. Shared frailty survival, generalised linear models and K-means clustering were applied. RESULTS: Sustained DORIS and LLDAS for ≥6 months occurred in 41.1% and 80.4%, respectively, and resulted in reduced damage accrual (HR: 0.58; 95% CI 0.36 to 0.93 and 0.61; 0.43 to 0.86) and severe flares (HR: 0.14; 0.08 to 0.27 and 0.19; 0.13 to 0.27). LLDAS without DORIS was also protective (HR: 0.65; 0.43 to 0.98 for damage, 0.49; 0.36 to 0.67 for flares). Models fitting increasing duration of targets showed that DORIS ≥50% and LLDAS ≥60% of time, or alternatively, ≥24 and ≥36 months, achieved optimal balance between feasibility (20.2-41.7%) and specificity (73.3-86.1%) for damage-free outcome. These targets were linked to reduced serious adverse events (risk ratio (RR): 0.56-0.71), hospitalisation (RR: 0.70) and mortality (RR: 0.06-0.13). Patients with predominant arthritis and mucocutaneous disease experienced reduced DORIS/LLDAS, compared with counterparts with major organ involvement. Conventional drugs were more frequently used in the former group, whereas potent immunosuppressive/biological agents in the latter. CONCLUSIONS: In moderate-to-severe SLE, sustained DORIS/LLDAS for at least 6 months is sufficient, while attainment for at least 24 months ensures higher specificity for damage-free progression, thus facilitating treat-to-target strategies and clinical trials. Arthritis and skin disease represent unmet therapeutic needs that could benefit from novel biologics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Rheumatology and Clinical Immunology, University of Crete School of Medicine, Heraklion, Greece.
- Laboratory of Autoimmunity and Inflammation, Centre of Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
- Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and University Hospital of Erlangen, Erlangen, Germany.
- Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S.Anna, Ferrara, Italy.
- Division of Rheumatology, Department of Medicine, University of Cyprus Medical School, Nicosia, Cyprus.
- Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, Attikon University Hospital, Joint Rheumatology Program, National and Kapodistrian University of Athens Medical School, Athens, Greece.
Förderung
- Pancretan Health Association
- Research Account of the University of Crete
Zitieren
APA
Pitsigavdaki, S., Nikoloudaki, M., Garantziotis, P., Silvagni, E., Repa, A., Marangoni, A., Flouri, I., Avgoustidis, N., Parperis, K., Fanouriakis, A., Govoni, M., Sidiropoulos, P., Boumpas, D. T., Bortoluzzi, A., & Bertsias, G. (2024). Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression. Annals of the Rheumatic Diseases, 83(4), 464-474. https://doi.org/10.1136/ard-2023-224919
Vancouver
Pitsigavdaki S, Nikoloudaki M, Garantziotis P, Silvagni E, Repa A, Marangoni A, et al. Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression. Annals of the Rheumatic Diseases. 2024;83(4):464-474. doi:10.1136/ard-2023-224919
BibTeX
@article{Pitsigavdaki2024,
author = {Pitsigavdaki, Sofia and Nikoloudaki, Myrto and Garantziotis, Panagiotis and Silvagni, Ettore and Repa, Argyro and Marangoni, Antonio and Flouri, Irini and Avgoustidis, Nestor and Parperis, Konstantinos and Fanouriakis, Antonis and Govoni, Marcello and Sidiropoulos, Prodromos and Boumpas, Dimitrios T and Bortoluzzi, Alessandra and Bertsias, George},
title = {Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression},
journal = {Annals of the Rheumatic Diseases},
year = {2024},
volume = {83},
number = {4},
pages = {464--474},
doi = {10.1136/ard-2023-224919}
}
EUVIMED